Petlife Pharmaceuticals, Inc.
PTLF · OTC
2/28/2018 | 11/30/2017 | 8/31/2017 | 5/31/2017 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $183 | $193 | $1,445 | $572 |
| SG&A Expenses | $183 | $193 | $1,445 | $572 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $270 | $0 |
| Operating Expenses | $183 | $193 | $1,715 | $572 |
| Operating Income | -$183 | -$193 | -$1,715 | -$572 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$244 | -$273 | -$284 | -$243 |
| Pre-Tax Income | -$427 | -$467 | -$1,999 | -$815 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$427 | -$467 | -$1,999 | -$815 |
| % Margin | – | – | – | – |
| EPS | -0.01 | -0.01 | 0 | -0.01 |
| % Growth | 0% | – | 100% | – |
| EPS Diluted | -0.01 | -0.01 | 0 | -0.01 |
| Weighted Avg Shares Out | 74,455 | 73,874 | 0 | 62,535 |
| Weighted Avg Shares Out Dil | 74,455 | 73,874 | 0 | 62,535 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $44 | $87 | $366 | $4 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$345 | -$380 | -$1,445 | -$774 |
| % Margin | – | – | – | – |